DXS International plc Director/Pdmr Shareholding

 
TIDMDXSP 
 
 
   DXS INTERNATIONAL PLC 
 
   Notification of Director / PDMR Dealing 
 
   The Board of DXS International plc (the "Company"), the AQSE Growth 
Market quoted clinical decision support developer and supplier of 
clinical decision support systems has received notification that on 10 
December 2020 Mr Bob Sutcliffe, the Chairman, purchased 13,333 Ordinary 
Shares in the Company at a price of 7.5p per share. 
 
   Following the transaction specified above Mr Sutcliffe has a beneficial 
holding of 545,382 Ordinary Shares representing 1.30% of the issued 
share capital of the Company. 
 
 
 
 
     Details of the person discharging managerial responsibilities 
1     / person closely associated 
---  ----------------------------------------------------------------------- 
a)   Name                                Robert Sutcliffe 
---  ----------------------------------  ----------------------------------- 
2    Reason for the notification 
---  ----------------------------------------------------------------------- 
a)   Position/status                     Chairman 
---  ----------------------------------  ----------------------------------- 
     Initial notification 
b)    /Amendment                         Initial 
---  ----------------------------------  ----------------------------------- 
     Details of the issuer, emission allowance market participant, 
3     auction platform, auctioneer or auction monitor 
---  ----------------------------------------------------------------------- 
a)   Name                                DXS INTERNATIONAL PLC 
---  ----------------------------------  ----------------------------------- 
b)   LEI                                 2138001R1KEUWTXEVJ44 
---  ----------------------------------  ----------------------------------- 
     Details of the transaction(s): section to be repeated for 
      (i) each type of instrument; (ii) each type of transaction; 
      (iii) each date; and (iv) each place where transactions 
4     have been conducted 
---  ----------------------------------------------------------------------- 
     Description of the financial 
      instrument, type of 
a)    instrument                         Ordinary Shares of 0.33p each 
--- 
 
     Identification code                 ISIN GB00B2Q6HZ92 
 
b)   Nature of the transaction           Purchase 
---  ----------------------------------  ----------------------------------- 
c)   Price(s) and volume(s) 
--- 
                                          Price(s)            Volume(s) 
---                                       ---------------  --------------- 
   7.5p                                                             13,333 
   ------------------------------------------------------  --------------- 
 
d)   Aggregated information 
--- 
 
 - Aggregated volume 
 
 - Price 
 
e)   Date of the transaction             10 December 2020 
---  ----------------------------------  ----------------------------------- 
f)   Place of the transaction            AQSE 
---  ----------------------------------  ----------------------------------- 
 
 
   The Directors of DXS International plc accept responsibility for this 
announcement 
 
   Enquiries: 
 
 
 
 
David Immelman (Chief Executive)               01252 719800 
 DXS International plc                david@dxs-systems.com 
Wrecclesham House 
 Wrecclesham Road 
 Farnham 
 Surrey 
 GU10 4PS 
www.dxs-systems.co.uk 
 
 
 
 
 
 
Corporate Advisor 
David Papworth 
 City & Merchant    0207 101 7676 
 
 
 
 
 
 
Corporate Broker 
Hybridan LLP 
 Claire Louise Noyce   020 3764 2341 
 
 
   Note to Editors: 
 
   DXS International presents up to date treatment guidelines and 
recommendations, from Clinical Commissioning Groups and other trusted 
NHS sources, to doctors, nurses and pharmacists in their workflow and 
during the patient consultation. This effective clinical decision 
support ultimately translates to improved healthcare outcomes delivered 
more cost effectively which should significantly contribute towards the 
NHS achieving its projected efficiency savings.
(END) Dow Jones Newswires
December 11, 2020 02:00 ET (07:00 GMT)
DXS (AQSE:DXSP)
Historical Stock Chart
From Jun 2024 to Jul 2024